IGF-1 LR3 is an IGF-1 LR3 peptide engineered as a long-acting analogue of insulin-like growth factor-1. Researchers use this recombinant peptide to study cell-growth regulation, IGF receptor activation, and metabolic signaling in controlled laboratory environments. Because IGF-1 LR3 includes a modified amino-acid sequence that reduces binding to IGF-binding proteins, it offers extended receptor availability compared with native IGF-1.
Scientists value the IGF-1 LR3 peptide for its ability to stimulate cellular proliferation, differentiation, and survival pathways in vitro. It supports studies focused on PI3K/AKT signaling, protein synthesis regulation, and anabolic cellular responses under defined conditions. In addition, the structural modifications in IGF-1 LR3 allow researchers to examine potency and duration differences between the analogue and the endogenous hormone.
Laboratories often choose the IGF-1 LR3 peptide for:
Analysing IGF-1 receptor signaling and downstream pathways
Studying growth-factor-driven cellular proliferation
Comparing receptor affinity between modified and native IGF-1
Exploring metabolic and anabolic responses in isolated models
Because IGF-1 LR3 provides predictable signaling kinetics and high bioactive stability, it supports precise mechanistic work and reproducible outcomes across replicate experiments. This makes the peptide suitable for rigorous cell-biology, metabolic-pathway, and molecular-regulation research.
Our IGF-1 LR3 peptide is supplied as a high-purity laboratory reagent intended only for qualified scientific professionals. It is not approved for clinical, diagnostic, therapeutic, or veterinary use. All research involving IGF-1 LR3 must comply with institutional safety policies and regulatory requirements for experimental bioregulatory compounds.
For research use only. Not for human consumption.
Not a researcher? Exit
